Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lower-dose boosted olaparib versus regular-dose olaparib
NL-OMON60436Phase 4Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of olaparib and cobicistat in cancer (3 arms), sponsored by Radboud University Medical Center. Primary endpoints: Part A olaparib AUC equivalence and Part B tolerability by dose reduction due to toxicity. Started Oct 2024; status: recruiting.
02
Drugs
olaparibcobicistat
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON60436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60436.